First-line #pembrolizumab monotherapy continued to show durable superiority over chemotherapy after 5 years of follow-up in #PD-L1–positive, locally advanced/metastatic NSCLC...

In phase III AUGMENT trial presented by Dr. John Leonard at the 2022 American Society of Hematology (ASH) Annual Meeting,...

On September 20, 2022, the #FDA approved #sodium_thiosulfate to reduce the risk of #ototoxicity associated with #cisplatin in pediatric patients...

#Niraparib maintenance provides a favorable OS trend compared with placebo in patients with platinum sensitive recurrent ovarian cancer regardless of...

In patients treated with 6 months of #oxaliplatin-based chemotherapy for stage III #colon_cancer, the prognostic impact of early discontinuation of...

In the randomized ALPINE trial, #Zanubrutinib (second-generation BTK inhibitor) improved the outcomes versus #ibrutinib (first-generation BTK inhibitor) in patients with...

On June 22, 2022, the #FDA granted an accelerated approval to #dabrafenib in combination with #trametinib for treatment of adult...

In a striking result presented at the ASTRO 2022 meeting, a randomized Phase II Trial have shown a survival benefit...

On November 10, 2022, the FDA approved #brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric...

In a large study reported in the New England journal of medicine, 147 out of 5547 patients (2.7%) with rectal...